Amino acid changes in regions of the CNS in relation to function in experimental portal-systemic encephalopathy
- PMID: 6150451
- DOI: 10.1007/BF00973042
Amino acid changes in regions of the CNS in relation to function in experimental portal-systemic encephalopathy
Abstract
Sustained hyperammonemia resulting from portocaval anastomosis (PCA) in the rat, is accompanied by neurological symptoms and reversible morphological changes in brain, the nature and distribution of which suggest selective vulnerability of certain brain structures. The present study was initiated to investigate the effects of increasing CNS ammonia on the distribution of amino acids in regions of the rat brain in relation to the degree of neurological impairment in PCA rats. Four weeks following PCA, rats were administered ammonium acetate (5.2 mmol/kg, i.p.) to precipitate neurological symptoms of encephalopathy which included diminished locomotor activity, loss of hindlimb extension and righting reflexes and ultimately coma. At various stages during the development of encephalopathy, rats were sacrificed and the amino acids glutamine, glutamate and aspartate measured simultaneously, using a sensitive double-isotope dansyl microassay. Homogenates of the following regions of the CNS were assayed: cerebral cortex, hippocampus, striatum, midbrain, hypothalamus, cerebellum, medulla-pons, spinal cord (gray matter) and spinal cord (white matter). Sustained hyperammonemia associated with PCA alone resulted in a non-uniform 2-4 fold increase of glutamine in all regions of the CNS. Glutamate, on the other hand, was selectively increased in striatum and cerebellum, two regions of brain shown to exhibit early morphologically-characterised astrocytic abnormalities in rats with PCA. Onset of severe neurological dysfunction was accompanied by significantly decreased glutamine and glutamate in striatum and cerebellum. Thus, sustained hyperammonemia in association with portocaval shunting results in region-selective effects with respect to glutamine-glutamate metabolism in the CNS.
Similar articles
-
Regional differences in the capacity for ammonia removal by brain following portocaval anastomosis.J Neurochem. 1988 Aug;51(2):486-90. doi: 10.1111/j.1471-4159.1988.tb01064.x. J Neurochem. 1988. PMID: 3392540
-
Cerebral aminoacids in portal-systemic encephalopathy: lack of evidence for altered gamma-aminobutyric acid (GABA) function.Metab Brain Dis. 1986 Sep;1(3):221-8. doi: 10.1007/BF01001783. Metab Brain Dis. 1986. PMID: 3508243
-
Maternal undernutrition during lactation: effect on amino acids in brain regions of offspring.J Neurochem. 1985 Dec;45(6):1802-8. doi: 10.1111/j.1471-4159.1985.tb10537.x. J Neurochem. 1985. PMID: 2865334
-
Ammonia: key factor in the pathogenesis of hepatic encephalopathy.Neurochem Pathol. 1987 Feb-Apr;6(1-2):1-12. doi: 10.1007/BF02833598. Neurochem Pathol. 1987. PMID: 3306479 Review.
-
Ultrastructural description of glutamate-, aspartate-, taurine-, and glycine-like immunoreactive terminals from five rat brain regions.J Electron Microsc Tech. 1990 May;15(1):49-66. doi: 10.1002/jemt.1060150106. J Electron Microsc Tech. 1990. PMID: 1971014 Review.
Cited by
-
Cerebrospinal fluid amino acids in relation to neurological status in experimental portal-systemic encephalopathy.Metab Brain Dis. 1991 Jun;6(2):65-74. doi: 10.1007/BF00999904. Metab Brain Dis. 1991. PMID: 1749365
-
Pathophysiology of hepatic encephalopathy: a new look at ammonia.Metab Brain Dis. 2002 Dec;17(4):221-7. doi: 10.1023/a:1021989230535. Metab Brain Dis. 2002. PMID: 12602499 Review.
-
Neuroactive amino acids in hepatic encephalopathy.Metab Brain Dis. 1996 Jun;11(2):165-73. doi: 10.1007/BF02069503. Metab Brain Dis. 1996. PMID: 8776718
-
Regional brain GABA metabolism and release during hepatic coma produced in rats chronically treated with carbon tetrachloride.Neurochem Res. 1988 Jan;13(1):37-44. doi: 10.1007/BF00971852. Neurochem Res. 1988. PMID: 3368028
-
Ammonia-induced swelling of rat cerebral cortical slices: implications for the pathogenesis of brain edema in acute hepatic failure.Metab Brain Dis. 1989 Sep;4(3):213-23. doi: 10.1007/BF01000297. Metab Brain Dis. 1989. PMID: 2796874